BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33692446)

  • 1. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
    Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
    Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S
    Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
    Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
    Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas.
    Hong L; Shi ZF; Li KK; Wang WW; Yang RR; Kwan JS; Chen H; Li FC; Liu XZ; Chan DT; Li WC; Zhang ZY; Mao Y; Ng HK
    Lab Invest; 2022 Jul; 102(7):731-740. PubMed ID: 35332262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
    Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
    Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
    Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
    Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
    Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
    Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
    Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
    Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.